Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
The HIV Prevention Trials Network (HPTN) 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) in preventing human immunodeficiency virus (HIV) in cisgender men and transgender women who have sex with men. We chara...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases Jg. 224; H. 9; S. 1581 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
16.11.2021
|
| Schlagworte: | |
| ISSN: | 1537-6613, 1537-6613 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The HIV Prevention Trials Network (HPTN) 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) in preventing human immunodeficiency virus (HIV) in cisgender men and transgender women who have sex with men. We characterized HIV infections that occurred in the blinded phase of HPTN 083.
Retrospective testing included HIV testing, viral load testing, quantification of study drugs, and HIV drug resistance testing.
Fifty-eight infections were evaluated, including 51 incident infections (12 in CAB arm and 39 in TDF/FTC arm). In many cases (5 in CAB arm and 37 in TDF/FTC arm), infection was associated with low or unquantifiable study drug concentrations. In 4 cases, infection occurred with on-time CAB-LA injections and expected plasma CAB concentrations. CAB exposure was associated with prolonged viral suppression and delayed antibody expression. In some cases, delayed HIV diagnosis resulted in CAB provision to participants with undetected infection, delayed antiretroviral therapy, and emergence of drug resistance; most of these infections would have been detected earlier with viral load testing.
Early detection of HIV infection and prompt antiretroviral therapy initiation could improve clinical outcomes in persons who become infected despite CAB-LA prophylaxis. Further studies are needed to elucidate the correlates of HIV protection in persons receiving CAB-LA. |
|---|---|
| AbstractList | The HIV Prevention Trials Network (HPTN) 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) in preventing human immunodeficiency virus (HIV) in cisgender men and transgender women who have sex with men. We characterized HIV infections that occurred in the blinded phase of HPTN 083.
Retrospective testing included HIV testing, viral load testing, quantification of study drugs, and HIV drug resistance testing.
Fifty-eight infections were evaluated, including 51 incident infections (12 in CAB arm and 39 in TDF/FTC arm). In many cases (5 in CAB arm and 37 in TDF/FTC arm), infection was associated with low or unquantifiable study drug concentrations. In 4 cases, infection occurred with on-time CAB-LA injections and expected plasma CAB concentrations. CAB exposure was associated with prolonged viral suppression and delayed antibody expression. In some cases, delayed HIV diagnosis resulted in CAB provision to participants with undetected infection, delayed antiretroviral therapy, and emergence of drug resistance; most of these infections would have been detected earlier with viral load testing.
Early detection of HIV infection and prompt antiretroviral therapy initiation could improve clinical outcomes in persons who become infected despite CAB-LA prophylaxis. Further studies are needed to elucidate the correlates of HIV protection in persons receiving CAB-LA. The HIV Prevention Trials Network (HPTN) 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) in preventing human immunodeficiency virus (HIV) in cisgender men and transgender women who have sex with men. We characterized HIV infections that occurred in the blinded phase of HPTN 083.BACKGROUNDThe HIV Prevention Trials Network (HPTN) 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) in preventing human immunodeficiency virus (HIV) in cisgender men and transgender women who have sex with men. We characterized HIV infections that occurred in the blinded phase of HPTN 083.Retrospective testing included HIV testing, viral load testing, quantification of study drugs, and HIV drug resistance testing.METHODSRetrospective testing included HIV testing, viral load testing, quantification of study drugs, and HIV drug resistance testing.Fifty-eight infections were evaluated, including 51 incident infections (12 in CAB arm and 39 in TDF/FTC arm). In many cases (5 in CAB arm and 37 in TDF/FTC arm), infection was associated with low or unquantifiable study drug concentrations. In 4 cases, infection occurred with on-time CAB-LA injections and expected plasma CAB concentrations. CAB exposure was associated with prolonged viral suppression and delayed antibody expression. In some cases, delayed HIV diagnosis resulted in CAB provision to participants with undetected infection, delayed antiretroviral therapy, and emergence of drug resistance; most of these infections would have been detected earlier with viral load testing.RESULTSFifty-eight infections were evaluated, including 51 incident infections (12 in CAB arm and 39 in TDF/FTC arm). In many cases (5 in CAB arm and 37 in TDF/FTC arm), infection was associated with low or unquantifiable study drug concentrations. In 4 cases, infection occurred with on-time CAB-LA injections and expected plasma CAB concentrations. CAB exposure was associated with prolonged viral suppression and delayed antibody expression. In some cases, delayed HIV diagnosis resulted in CAB provision to participants with undetected infection, delayed antiretroviral therapy, and emergence of drug resistance; most of these infections would have been detected earlier with viral load testing.Early detection of HIV infection and prompt antiretroviral therapy initiation could improve clinical outcomes in persons who become infected despite CAB-LA prophylaxis. Further studies are needed to elucidate the correlates of HIV protection in persons receiving CAB-LA.CONCLUSIONSEarly detection of HIV infection and prompt antiretroviral therapy initiation could improve clinical outcomes in persons who become infected despite CAB-LA prophylaxis. Further studies are needed to elucidate the correlates of HIV protection in persons receiving CAB-LA. |
| Author | Landovitz, Raphael J Bushman, Lane R Pryluka, Daniel Anderson, Peter Marzinke, Mark A Middelkoop, Keren Hendrix, Craig W Li, Maoji St Clair, Marty Eshleman, Susan H Gaur, Aditya Haines, Casey D Persaud, Deborah Rooney, James F Petropoulos, Christos Donnell, Deborah Rinehart, Alex McCauley, Marybeth Fogel, Jessica M Piwowar-Manning, Estelle Phanuphak, Nittaya Weng, Lei Hanscom, Brett Cohen, Myron S Ahmed, Shahnaz Kofron, Ryan Coelho, Lara Grinsztejn, Beatriz Adeyeye, Adeola Cummings, Vanessa |
| Author_xml | – sequence: 1 givenname: Mark A surname: Marzinke fullname: Marzinke, Mark A organization: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA – sequence: 2 givenname: Beatriz surname: Grinsztejn fullname: Grinsztejn, Beatriz organization: Instituto de Pesquisa Clinica Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil – sequence: 3 givenname: Jessica M surname: Fogel fullname: Fogel, Jessica M organization: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA – sequence: 4 givenname: Estelle surname: Piwowar-Manning fullname: Piwowar-Manning, Estelle organization: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA – sequence: 5 givenname: Maoji surname: Li fullname: Li, Maoji organization: Fred Hutchinson Cancer Research Center, Seattle, Washington, USA – sequence: 6 givenname: Lei surname: Weng fullname: Weng, Lei organization: Fred Hutchinson Cancer Research Center, Seattle, Washington, USA – sequence: 7 givenname: Marybeth surname: McCauley fullname: McCauley, Marybeth organization: FHI 360, Durham, North Carolina, USA – sequence: 8 givenname: Vanessa surname: Cummings fullname: Cummings, Vanessa organization: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA – sequence: 9 givenname: Shahnaz surname: Ahmed fullname: Ahmed, Shahnaz organization: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA – sequence: 10 givenname: Casey D surname: Haines fullname: Haines, Casey D organization: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA – sequence: 11 givenname: Lane R surname: Bushman fullname: Bushman, Lane R organization: University of Colorado, Aurora, Colorado, USA – sequence: 12 givenname: Christos surname: Petropoulos fullname: Petropoulos, Christos organization: Monogram Biosciences, South San Francisco, California, USA – sequence: 13 givenname: Deborah surname: Persaud fullname: Persaud, Deborah organization: Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA – sequence: 14 givenname: Adeola surname: Adeyeye fullname: Adeyeye, Adeola organization: Prevention Science Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA – sequence: 15 givenname: Ryan surname: Kofron fullname: Kofron, Ryan organization: Department of Medicine, University of California at Los Angeles, Los Angeles, California, USA – sequence: 16 givenname: Alex surname: Rinehart fullname: Rinehart, Alex organization: ViiV Healthcare, Research Triangle Park, North Carolina, USA – sequence: 17 givenname: Marty surname: St Clair fullname: St Clair, Marty organization: ViiV Healthcare, Research Triangle Park, North Carolina, USA – sequence: 18 givenname: James F surname: Rooney fullname: Rooney, James F organization: Gilead Sciences, Foster City, California, USA – sequence: 19 givenname: Daniel surname: Pryluka fullname: Pryluka, Daniel organization: Hospital Velez Sarfield, Buenos Aires, Argentina – sequence: 20 givenname: Lara surname: Coelho fullname: Coelho, Lara organization: Instituto de Pesquisa Clinica Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil – sequence: 21 givenname: Aditya surname: Gaur fullname: Gaur, Aditya organization: St Jude Children's Research Hospital, Memphis, Tennessee, USA – sequence: 22 givenname: Keren surname: Middelkoop fullname: Middelkoop, Keren organization: Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa – sequence: 23 givenname: Nittaya surname: Phanuphak fullname: Phanuphak, Nittaya organization: Center of Excellence in Transgender Health, Chulalongkorn University, Bangkok, Thailand – sequence: 24 givenname: Myron S surname: Cohen fullname: Cohen, Myron S organization: Department of Medicine, University of North Carolina, North Carolina, USA – sequence: 25 givenname: Craig W surname: Hendrix fullname: Hendrix, Craig W organization: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA – sequence: 26 givenname: Peter surname: Anderson fullname: Anderson, Peter organization: University of Colorado, Aurora, Colorado, USA – sequence: 27 givenname: Brett surname: Hanscom fullname: Hanscom, Brett organization: Fred Hutchinson Cancer Research Center, Seattle, Washington, USA – sequence: 28 givenname: Deborah surname: Donnell fullname: Donnell, Deborah organization: Fred Hutchinson Cancer Research Center, Seattle, Washington, USA – sequence: 29 givenname: Raphael J surname: Landovitz fullname: Landovitz, Raphael J organization: Center for Clinical AIDS Research & Education, University of California, Los Angeles, Los Angeles, California, USA – sequence: 30 givenname: Susan H surname: Eshleman fullname: Eshleman, Susan H organization: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33740057$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkMtOwzAQRS0E4lHYskSzhEXBiRMnZYciIJV4CQpdVn5MWleNXeykAr6NjyMUkFjN6Oro3NHskU3rLBJyGNHTiA7YmbGVNuFsboSM0niD7EYpy_qcR2zz375D9kKYU0oTxrNtssNYllCaZrvks5gJL1SD3nyIxjgLroKyrYWFYV231mmsjDJo1Tu8GN8GOC6HLycwtBWqNW8sFCZM0Wr0cIsWhNUw8sL-ZWNXd-l45qAUK4QnfIOxaWZr9hEVmpWx004474RCLhAKIV2DUy9WxkPlPHSN8OBxhfa78RzKh9Ed0Jztk61KLAIe_M4eeb66HBVl_-b-elhc3PRVksZNPxmkXOWploNMKSYlzWKqeS4TncQ8x4xyqaiilHGR5JFUTOc8GsRSRro7T-Zxjxz_eJfevbYYmkltgsLFQlh0bZjEKWVJV8VZhx79oq2sUU-W3tTCv0_-Ph5_AfLghxU |
| CitedBy_id | crossref_primary_10_1002_cpt_3447 crossref_primary_10_1016_j_ajem_2023_07_041 crossref_primary_10_1128_aac_00053_23 crossref_primary_10_1097_QAI_0000000000003012 crossref_primary_10_1136_bmjopen_2023_083146 crossref_primary_10_1177_09564624231152781 crossref_primary_10_1056_NEJMoa2411858 crossref_primary_10_1093_cid_ciad021 crossref_primary_10_1038_s41467_023_36330_5 crossref_primary_10_1186_s13722_024_00482_6 crossref_primary_10_1111_bcp_15477 crossref_primary_10_1097_QAI_0000000000002889 crossref_primary_10_1002_puh2_182 crossref_primary_10_1097_COH_0000000000000919 crossref_primary_10_4102_sajhivmed_v24i1_1497 crossref_primary_10_1016_j_jpba_2023_115307 crossref_primary_10_1007_s40265_023_01963_9 crossref_primary_10_1080_17425247_2022_2135699 crossref_primary_10_1016_j_glohj_2024_04_002 crossref_primary_10_1089_apc_2024_0158 crossref_primary_10_1016_j_whi_2021_12_005 crossref_primary_10_1093_cid_ciab913 crossref_primary_10_1007_s11095_022_03440_6 crossref_primary_10_1097_JNC_0000000000000488 crossref_primary_10_1016_j_ejmech_2023_115586 crossref_primary_10_1186_s12865_025_00687_7 crossref_primary_10_1016_S0140_6736_23_01381_8 crossref_primary_10_2196_46767 crossref_primary_10_1016_j_ebiom_2023_104764 crossref_primary_10_1097_QAD_0000000000004099 crossref_primary_10_1136_jcp_2025_210202 crossref_primary_10_1002_cpt_2801 crossref_primary_10_1111_vox_13587 crossref_primary_10_1371_journal_pntd_0011548 crossref_primary_10_1016_S2352_3018_23_00051_6 crossref_primary_10_1093_cid_ciac685 crossref_primary_10_1007_s40265_022_01791_3 crossref_primary_10_1080_13543784_2023_2178415 crossref_primary_10_1097_COH_0000000000000729 crossref_primary_10_1016_S2352_3018_22_00251_X crossref_primary_10_1038_s41467_024_54783_0 crossref_primary_10_1097_QAD_0000000000003644 crossref_primary_10_1016_S2352_3018_23_00261_8 crossref_primary_10_1093_jac_dkac252 crossref_primary_10_1097_COH_0000000000000801 crossref_primary_10_1172_JCI167818 crossref_primary_10_1038_s41579_023_00914_1 crossref_primary_10_1038_s41598_022_11020_2 crossref_primary_10_1016_S2352_3018_21_00153_3 crossref_primary_10_1007_s11904_022_00616_y crossref_primary_10_1016_j_ijid_2024_107222 crossref_primary_10_1111_bcp_15410 crossref_primary_10_1056_NEJMoa2101016 crossref_primary_10_1016_S2352_3018_22_00331_9 crossref_primary_10_1002_phar_2922 crossref_primary_10_1007_s10461_022_03816_0 crossref_primary_10_1089_aid_2024_0049 crossref_primary_10_1093_infdis_jiac415 crossref_primary_10_1016_j_tmrv_2023_150754 crossref_primary_10_1093_cid_ciae572 crossref_primary_10_1097_MOP_0000000000001357 crossref_primary_10_1002_jia2_25896 crossref_primary_10_1016_j_yamp_2023_07_003 crossref_primary_10_1097_01_JAA_0000911184_87186_0f crossref_primary_10_1016_S2352_3018_23_00200_X crossref_primary_10_1097_COH_0000000000000733 crossref_primary_10_15585_mmwr_rr7401a1 crossref_primary_10_1097_COH_0000000000000735 crossref_primary_10_1002_jia2_25892 crossref_primary_10_1097_COH_0000000000000894 crossref_primary_10_1097_QAD_0000000000003494 crossref_primary_10_7326_ANNALS_25_01885 crossref_primary_10_1016_j_diagmicrobio_2023_115951 crossref_primary_10_1093_ofid_ofac191 crossref_primary_10_1016_S2352_3018_22_00365_4 crossref_primary_10_1016_j_antiviral_2022_105427 crossref_primary_10_1038_s41586_021_04279_4 crossref_primary_10_1016_S0140_6736_22_00538_4 crossref_primary_10_1128_aac_00994_24 crossref_primary_10_1128_spectrum_00307_24 crossref_primary_10_1089_apc_2022_0068 crossref_primary_10_1093_infdis_jiab576 crossref_primary_10_1097_QAI_0000000000003308 crossref_primary_10_3390_v15091932 crossref_primary_10_1097_COH_0000000000000746 crossref_primary_10_1002_jia2_26491 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. |
| Copyright_xml | – notice: The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/infdis/jiab152 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1537-6613 |
| ExternalDocumentID | 33740057 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: U01 AI069476 – fundername: NIAID NIH HHS grantid: UM1 AI069536 – fundername: NIAID NIH HHS grantid: P30 AI050410 – fundername: NIAID NIH HHS grantid: UM1 AI068613 – fundername: NIAID NIH HHS grantid: UM1 AI068619 – fundername: NIAID NIH HHS grantid: UM1 AI069424 – fundername: NIAID NIH HHS grantid: UM1 AI069476 – fundername: NIAID NIH HHS grantid: UM1 AI068617 |
| GroupedDBID | --- -DZ -~X ..I .2P .I3 .XZ .ZR 08P 0R~ 123 29K 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 70D 85S AABZA AACGO AACZT AAHBH AAHTB AAJKP AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACGOD ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BR6 BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 D-I DAKXR DIK DILTD DU5 D~K EBS ECGQY ECM EE~ EIF EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IH2 IOX J21 JLS JSG JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 MHKGH MJL ML0 N9A NGC NOMLY NOYVH NPM NU- O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SJN TCURE TEORI TJX TR2 W2D W8F WH7 X7H YAYTL YKOAZ YXANX ~91 7X8 |
| ID | FETCH-LOGICAL-c452t-4956c85db97cc3bb0720d68b4d4268e706bc0c0036a481bc3d86192bb1deceb82 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 90 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000728427500016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1537-6613 |
| IngestDate | Sun Sep 28 00:30:03 EDT 2025 Mon Jul 21 02:02:59 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | injectable HIV preexposure prophylaxis HPTN 083 TDF/FTC cabotegravir long-acting men who have sex with men prevention |
| Language | English |
| License | The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c452t-4956c85db97cc3bb0720d68b4d4268e706bc0c0036a481bc3d86192bb1deceb82 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/8599849 |
| PMID | 33740057 |
| PQID | 2503445263 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2503445263 pubmed_primary_33740057 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-11-16 |
| PublicationDateYYYYMMDD | 2021-11-16 |
| PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of infectious diseases |
| PublicationTitleAlternate | J Infect Dis |
| PublicationYear | 2021 |
| SSID | ssj0004367 |
| Score | 2.6199324 |
| Snippet | The HIV Prevention Trials Network (HPTN) 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1581 |
| SubjectTerms | Adolescent Adult Anti-HIV Agents - administration & dosage Diketopiperazines - administration & dosage Female HIV Infections - epidemiology HIV Infections - prevention & control HIV Integrase Inhibitors - administration & dosage Homosexuality, Male Humans Incidence Male Middle Aged Pre-Exposure Prophylaxis Pyridones - administration & dosage Retrospective Studies Transgender Persons Viral Load - drug effects |
| Title | Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33740057 https://www.proquest.com/docview/2503445263 |
| Volume | 224 |
| WOSCitedRecordID | wos000728427500016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NbxMxELWAAuJCS4BSKNUgcWgPq2zizXrDBaGoVXJIFImS5Bbt2N7WHLxtNo3gv_HjmPFuAhckpF72sNoPy2N7nscz7wnxEeM0LpDmd5GhihKlTYR9xChWVvdkgiq2SRCbUJNJtlj0p03ArWrSKrdrYlioTak5Rt4mVy0T1sOWn29uI1aN4tPVRkLjodiTBGU4pUst_mILl0FBlia1isgPyR1po2yT-Yyr2t9djh0uOvoXvAxu5mL_vg08EM8bgAlf6hHxQjywviWe1JKTP1vi6bg5TH8pfg12ZM11LSaUBYSgPoy4aqQ0lukluDYTZm51V8HpcDQ7g1GTv-XBeRi46iqo0cHYesi9geD9mntBHxPm1yUM842Fr_YHzN36OjxLgNU6DmfQBzkYxDVcMKAxGfgrNm4FhKeB_ghbmqnSf4Lh9HICBOheiW8X55eDYdSIOUSaOmUd8UZMZz2DfaW1RIxVNzZphokhjJBZFaeoY830OHlCUFpLk_HeDrFjqDmYdV-LR7709o2AQlmZStsrCp0lushRailT2ml3QlmxORIfthZa0mThE5Dc2_KuWv6x0ZE4rM28vKlZPZZSqoRLc9_-x9vvxLMu57ZwOmB6LPYKWirse_FYb9auWp2EUUjXyXT8G30Z6Wg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterization+of+Human+Immunodeficiency+Virus+%28HIV%29+Infection+in+Cisgender+Men+and+Transgender+Women+Who+Have+Sex+With+Men+Receiving+Injectable+Cabotegravir+for+HIV+Prevention%3A+HPTN+083&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Marzinke%2C+Mark+A&rft.au=Grinsztejn%2C+Beatriz&rft.au=Fogel%2C+Jessica+M&rft.au=Piwowar-Manning%2C+Estelle&rft.date=2021-11-16&rft.eissn=1537-6613&rft.volume=224&rft.issue=9&rft.spage=1581&rft_id=info:doi/10.1093%2Finfdis%2Fjiab152&rft_id=info%3Apmid%2F33740057&rft_id=info%3Apmid%2F33740057&rft.externalDocID=33740057 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6613&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6613&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6613&client=summon |